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Background
Decitabine was evaluated for its efficacy and safety in Korean patients with myelodysplastic
syndrome with IPSS score of 0.5 or over. 
Design and Methods
Decitabine 20 mg/m2/day was given intravenously over one hour for five consecutive days
every four weeks. The primary end point was overall response rate. 
Results
A total of 101 patients were analyzed. The International Prognostic Scoring System risk cate-
gory was Intermediate-2/High in 47.5%. A median of 5 courses (range 1-18) were delivered.
The overall response rate was 55.4% (13 complete responses, one partial response, 23 marrow
complete responses, and 19 hematologic improvements). Forty-eight patients (47.5%) showed
some hematologic improvement. With a median follow-up duration of 478 days (range 69-
595), median overall survival was 17.7 months. Patients who showed hematologic improve-
ment had significantly longer overall survival than those who did not (19.2 vs. 15.9 months,
P=0.006 by landmark analysis at six months). The difference in overall survival was evident in
the Intermediate-2/High risk group but not in the Intermediate-1 risk group. The progression-
free survival and acute myeloid leukemia-free survival were 61.9% and 77.9% at one year,
respectively. Among 489 assessable treatment courses, there were 97 fever episodes requiring
intravenous antimicrobials. 
Conclusions
Decitabine treatment was feasible and effective in Korean patients with myelodysplastic syn-
drome, and the overall survival was significantly longer in patients showing hematologic
improvement. (ClinicalTrials.gov Identifier: NCT01041846)
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Introduction
Myelodysplastic syndrome (MDS) is a clonal hematopoi-
etic stem cell disorder characterized by ineffective
hematopoiesis and peripheral cytopenias. The natural his-
tory of this syndrome ranges from more indolent forms of
the disease over years, to those with a rapid evolution to
acute myeloid leukemia (AML). MDS shows a high preva-
lence of tumor suppressor gene hypermethylation1 and
DNA methylation is believed to contribute to cancer initi-
ation and progression by gene expression inactivation.2,3
Decitabine (5-aza-2’-deoxycytidine) is a cytosine nucle-
oside analog which is incorporated into DNA. At lower
doses, decitabine induces hypomethylation, which may
induce cell differentiation, re-expression of tumor suppres-
sor genes, and inhibition of tumor growth.4,5
The drug is approved for the treatment of myelodys-
plastic syndrome (MDS) including previously treated or
untreated de novo or secondary MDS of all FAB subtypes,
and intermediate (INT)-1, INT-2 and high-risk
International Prognostic Scoring System (IPSS) groups.6
Possible mechanisms of clinical effects of decitabine
include direct cytotoxicity and hypomethylation.1,7
Phase II and III clinical trials have demonstrated the effi-
cacy of decitabine in the treatment of patients with MDS.
In an initial phase II trial, decitabine was administered
every six weeks as a continuous intravenous infusion of 50
mg/m2/day for three days (150 mg/m2 per course), and
response was observed in 54% of 28 evaluable patients.8
Subsequently, a phase II and two phase III trials investigat-
ed a modified 3-day regimen, in which decitabine was
given intravenously over three hours at a dose of 15
mg/m2 every eight hours for three days (135 mg/m2 per
course) and each course was repeated every six weeks.
These trials showed overall response rates of 30-49%.9-11
The US Food and Drug Administration approved this 3-
day regimen for the treatment of patients with MDS. The
alternative 5-day regimen, in which decitabine 20
mg/m2/day is administered as a one hour intravenous infu-
sion for five consecutive days (100 mg/m2 per course)
every four weeks, was subsequently also approved. This
regimen is the most widely used because it is suitable for
treatment in an outpatient clinic and achieved a higher
response rate in a randomized trial of three schedules.12 A
recent phase II trial using the 5-day regimen showed
meaningful clinical benefit for patients with MDS, with
more than half of the patients showing improvement.13
These clinical trials demonstrating the efficacy of
decitabine in the treatment of patients with MDS were
performed in Western countries; there have been few data
on the effects of decitabine in Asian MDS patients.14 Thus,
we performed a prospective multicenter observational
study of the 5-day decitabine regimen in Korean patients
with MDS.
Design and Methods
Patients
Study eligibility criteria were: older than 17 years of age, and
MDS (de novo or secondary) of any subtype as defined by the
WHO classification with an IPSS score of 0.5 or more or chronic
myelomonocytic leukemia (CMML). Patients were excluded if
they had previously received any hypomethylating therapy or if
they had severe coexisting disease. Pregnant or lactating women
were also excluded. Patients had to have adequate renal and
hepatic function, and good performance status (Eastern
Cooperative Oncology Group performance status of 0 to 2). This
study was approved by the institutional review boards of all par-
ticipating centers. Patients provided informed consent before reg-
istration on this prospective multicenter observational study. This
trial is registered at www.clinicaltrials.gov as #NCT01041846.
Treatment
Decitabine was given intravenously over one hour at a dose of
20 mg/m2 daily for five consecutive days and each course was
repeated every four weeks in the outpatient clinic. General guide-
lines for dose adjustments, treatment intervals, treatment dura-
tion, and response assessments by bone marrow examination
were provided. No dose escalation of decitabine was allowed.
Dose reduction or treatment delay could be determined at the dis-
cretion of the treating physicians, but no dose reduction or treat-
ment delay was recommended, at least in the first 3 courses,
regardless of blood counts. Exceptions to this were: presence of
grade 3 or 4 non-hematologic toxicities, occurrence of life-threat-
ening myelosuppression complications, such as bleeding or infec-
tion, or persistent myelosuppression defined by bone marrow
hypocellularity without evidence of disease progression over six
weeks after start of decitabine treatment. Dose reductions were
made to 15 mg/m2/day, 10 mg/m2/day, and 7.5 mg/m2/day.
Physicians were advised to continue decitabine treatment for at
least 4 courses or until disease progression or death, unacceptable
adverse events, or withdrawal from the study by the patient, and
to perform bone marrow examination every 2 courses until a com-
plete remission (CR) was confirmed. Prophylactic antimicrobials
or hematopoietic growth factors and other supportive care were
given at the discretion of the treating physician. 
Study end points
The primary end point of this study was overall response rate
(ORR). Treatment response was assessed by a central reviewer
using modified International Working Group (IWG 2006) response
criteria.15 The ORR included rates for CR, marrow CR (mCR), par-
tial response (PR), and hematologic improvements (HI). Secondary
end points were adverse events, cytogenetic response and time-to-
event outcomes of overall survival (OS), progression-free survival
(PFS), and time to AML evolution (TTA), calculated from the initial
date of decitabine treatment to the date of death from any cause
(OS), and to the date of disease progression or death from MDS
(PFS).15 Adverse events were graded according to the Common
Toxicity Criteria for Adverse Events version 3.0
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/c
tcaev3.pdf).
Statistical analysis
The χ2 test was used for comparison of categorical variables
such as prognostic factors for treatment response. Time-to-event
outcomes were calculated using the Kaplan-Meier product limit
estimates and were compared by log rank test. When we analyzed
the associations between survival and response to decitabine, we
used a landmark analysis to avoid the length bias associated with
time-dependent variables.16,17 Time zero for this analysis was cho-
sen a priori as six months because all initial responses to decitabine
were achieved within six months after the start of decitabine treat-
ment. Outcome differences at landmark time were compared
using the log rank test. Multivariate analysis was performed using
a stepwise multiple logistic regression for ORR achievement and
using Cox’s proportional hazard model for OS. The database was
locked one year after enrollment of the last patient, on September
30, 2010.
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Results
Patients’ characteristics
A total of 103 patients were enrolled into this study
between December 2008 and September 2009 from 24
Korean institutes. Two patients left the study because
bone marrow diagnosis review showed idiopathic
myelofibrosis and AML, respectively. Thus, 101 patients
(68 males and 33 females) were included in the analyses.
Median age was 65 years (range 23-80 years) and median
duration of MDS was 25 days (range 1-1,797 days). Ninety
patients had de novo MDS, 5 had therapy-related MDS,
and 6 had MDS evolving from aplastic anemia. WHO sub-
types at study entry were refractory anemia (RA; n=4),
refractory cytopenia with multilineage dysplasia (RCMD;
n=24), RCMD with ringed sideroblasts (n=3), refractory
anemia with excess of blasts (RAEB-1; n=26 and RAEB-2;
n=32), unclassifiable (n=1), and CMML (n=11). The IPSS
risk category was Intermediate (INT)-1 in 52 patients,
INT-2 or High in 48, and unknown in one whose IPSS
score was at least 0.5 but whose karyotype was not avail-
able. Thirty-seven patients had abnormal karyotype
before decitabine treatment; IPSS risk stratification of
cytogenetic findings was good (n=65), intermediate
(n=15), poor (n=19), and unknown (n=1). At the time of
decitabine treatment, 33 patients were RBC transfusion-
dependent and 27 were platelet transfusion-dependent.
Treatment data
Median number of courses delivered was 5 (range 1-18).
Twenty-seven patients (26.7%) discontinued decitabine
treatment before 3 courses because of treatment failure
(n=10), allogeneic HCT (n=3), adverse effects (n=7), and
personal reasons (n=7). Thirty-six patients (35.6%)
received more than 6 courses and 15 patients were still on
decitabine treatment at the time of analysis. Mean interval
(± standard deviation) between treatment courses was
34.0±9.5 days and there was no significant difference in
the intervals according to the treatment course number.
Decitabine dose modification or treatment delay was
made only in 4.2% of patients within the first 3 courses.
Treatment response
The response was observed in 56 (55.4%; 95% confi-
dence interval [CI], 45.7-65.1%) among 101 patients: 13
CR (12.9%), one PR (1.0%), 15 mCR with HI (14.9%), 8
mCR without HI (7.9%), and 19 HI only (18.8%) (Table 1).
Sixty-seven patients (66.3%) showed stable disease (SD)
or better. Forty-eight patients (47.5%) experienced HI: 1-
lineage improvement in 22, 2-lineage improvement in 15,
and 3-lineage improvement in 11. Erythroid improvement
(HI-E) was observed in 35 (36.1%) of 97 patients whose
initial hemoglobin was less than 11.0 g/dL, platelet
improvement (HI-P) in 30 (43.5%) of 69 patients whose
initial platelets were less than 100¥109/L, and neutrophil
improvement in 20 (37.7%) of 53 patients whose initial
neutrophils were less than 1¥109/L. Cytogenetic response
could be evaluated in 17 patients: cytogenetic CR was
achieved in 5 (29.4%) and cytogenetic PR in 2 (11.8%). 
Initial response was detected during the first 2 courses in
45 (80.4%) of 56 patients with response (Figure 1). Median
time to response was 1.9 months (range 0.9-5.2 months)
and median duration of response was 13.2 months (95%
CI, 9.3-17.1 months). Median number of treatment cours-
es to achieve any HI, HI-E, HI-P, and HI-N was 2 (range 1-
6), 2 (range 1-5), 1 (range 1-4), and 3 (range 1-8), respec-
tively. 
There was no significant difference in ORR according to
baseline patients’ characteristics. Although patients who
were RBC or platelet transfusion-dependent showed a
tendency of lower ORR than those who were not (Table
2), stepwise multiple logistic regression analysis did not
identify any independent prognostic factor for ORR.
Adverse events
Averse events were evaluated for the first 8 courses for
all patients, for a total of 489 courses. Major adverse
events were cytopenia and cytopenia-related infection.
Grade III or IV anemia (51.5%), neutropenia (80.2%), and
thrombocytopenia (53.0%) were frequently observed.
Febrile episodes requiring intravenous antibiotics and hos-
pitalization occurred in 97 (19.8%) of 489 cycles evaluat-
ed: febrile neutropenia in 55, pneumonia in 12, fungal
Decitabine in Korean patients with MDS
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Table 1. Response to decitabine treatment.
Response by IWG 2006 criteria                      N. of patients (%)
CR                                                                                        13 (12.9%)
PR                                                                                          1 (1.0%)
mCR with HI                                                                      15 (14.9%)
mCR without HI                                                                 8 (7.9%)
HI only                                                                                19 (18.8%)
SD                                                                                        11 (10.9%)
Failure                                                                                  7 (6.9%)
Not assessable                                                                 27 (26.7%)
CR + PR                                                                             14 (13.9%)
CR + PR + mCR                                                               37 (36.6%)
ORR (CR + PR + mCR + HI)                                       56 (55.4%)
CR + PR + mCR + HI + SD                                          67 (66.3%)
IWG: International Working Group; CR: complete response; PR: partial response; mCR:
marrow complete response; ORR: overall response rate; HI: hematologic improvement;
SD: stable disease.
Figure 1. Time to initial response, according to treatment course, in
56 patients who attained complete response, partial response, mar-
row complete response or hematologic improvement.
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infection in 12, urinary tract infections in 4, cellulitis in 4,
tonsillitis/sinusitis in 3, viral infection in 2, septicemia in 2,
abscess in 2, and tuberculosis in one. There was a signifi-
cant difference in the incidence of a febrile episode accord-
ing to the treatment course number: 28.7% during the first
3 courses versus 9.6% during the 4th to 8th courses
(P<0.001). A total of 13 episodes of grade III bleeding were
observed: 12 episodes within the first 3 courses and one in
the 6th course. There was no life-threatening bleeding
episode. Grade III or higher non-hematologic toxicities
were infrequent and reversible.
Survival data
With a median follow-up duration among surviving
patients of 478 days (range 69-595 days), 44 patients died,
42 showed disease progression, and 19 progressed to
AML. Median overall survival was 17.7 months (95% CI,
16.6-18.9 months). Probabilities for OS, PFS, and AML-
free survival at one year were 74.8%, 61.9%, and 77.9%,
respectively.
Baseline characteristics except RBC transfusion-depen-
dency, did not have a significant impact on OS (Table 2).
Patients with RBC transfusion-dependency at baseline had
inferior survival than those without (median OS 16.6 vs.
18.1 months; P=0.038) and RBC transfusion-dependency
was the only prognostic factor for OS in Cox’s proportion-
al hazard model (hazard ratio 1.937; 95% CI, 1.043-3.596;
P=0.036). Patients who reached CR or PR had a meaning-
ful survival (only one of 14 patients died), while patients
with mCR showed similar OS to those with HI or SD
(median OS 17.7 vs. 18.2 months; Figure 2A). Patients who
progressed or who could not be assessed had the poorest
survival (median OS 14.4 months). Among 23 patients
with mCR, OS differed according to presence of accompa-
nying HI (17.7 vs. 14.4 months; P=0.074 by landmark
analysis at six months; Figure 2B). Thus, achievement of
HI appeared to be important for OS and we analyzed the
impact of HI on survival both in all patients and according
J-H Lee et al.
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Table 2. Prognostic factor analysis for overall response (CR/PR/mCR/HI)
and overall survival.
ORR P value OS, median, P value
months
Age, year
65 or less 30/55 (54.5%) 0.842 18.2 0.584
Over 65 26/46 (56.5%) 17.7
Sex
Male 38/68 (55.9%) 0.899 17.7 0.764
Female 18/33 (54.5%) 17.3
Duration of MDS
≤ 1 year 49/88 (55.7%) 0.901 17.7 0.722
> 1 year 7/13 (53.8%) 18.9
WHO subtype
RA/RARS/MDS-U 4/5 (80.0%) 0.369 19.2 0.069
RCMD/RCMD-RS 11/27 (40.7%) 17.7
RAEB-1 15/26 (57.7%) 18.0
RAEB-2 20/32 (62.5%) 17.3
CMML 6/11 (54.5%) 14.2
RBC transfusion-dependency
No 42/68 (61.8%) 0.067 18.1 0.038
Yes 14/33 (42.4%) 16.6
Platelet transfusion-dependency
No 45/74 (60.8%) 0.072 17.7 0.226
Yes 11/27 (40.7%) 18.0
IPSS cytogenetic risk category
Good 38/65 (58.5%) 0.681 18.0 0.413
Intermediate 8/15 (53.3%) N/R
High 9/19 (47.4%) 17.7
IPSS risk category
INT-1 26/52 (50.0%) 0.296 18.1 0.075
INT-2/High 29/48 (55.1%) 16.8
CR: complete response; PR: partial response; mCR: marrow complete response; HI: hema-
tologic improvement; ORR: overall response rate; OS: overall survival; RA: refractory ane-
mia; RARS: RA with ringed sideroblasts; MDS-U: unclassifiable MDS; RCMD: refractory
cytopenia with multilineage dysplasia; RCMD-RS: RCMD with ringed sideroblasts; RAEB:
refractory anemia with excess of blasts; CMML: chronic myelomonocytic leukemia; N/R:
not reached; IPSS: International Prognostic Scoring System; INT: intermediate.
Figure 2. (A) Overall survival according to treatment response type. (B) Overall survival in patients who achieved mCR with or without HI. P
value by landmark analysis with the landmark set at six months from the initial date of decitabine treatment. CR: complete response; PR:
partial response; HI: hematologic improvement; SD: stable disease; mCR: marrow complete response; DP: disease progression; NA: not
assessable.
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to IPSS risk subgroup (lower risk including IPSS INT-1 and
higher risk including IPSS INT-2/High). Patients who
achieved HI had significantly longer OS than those who
did not (median OS 19.2 vs. 15.9 months; P=0.006 by land-
mark analysis at six months; Figure 3A). In a subgroup
analysis, achievement of HI had significant impact on OS
in higher risk patients (median OS 19.2 vs. 13.1 months;
P=0.008 by landmark analysis at six months; Figure 3B),
whereas it did not in lower risk patients (median OS 18.0
vs. 18.1 months; P=0.205 by landmark analysis at six
months; Figure 3C).
Allogeneic hematopoietic cell transplantation
A total of 15 patients received allogeneic HCT after a
median 4 courses (range 2-12) of decitabine treatment.
Median duration from start of decitabine treatment to
HCT was 147 days (range 103-501 days). At the time of
HCT, 4 patients were in remission (one PR, 3 mCR), one
in HI, 6 in SD or DP, and 3 in AML progression. After
median follow-up duration of 252 days (range 36-434
days) among surviving patients, 5 patients died from AML
progression (n=3) or transplant-related mortality (n=2).
Median survival after allogeneic HCT was 323 days (95%
CI, 306-340 days).
Discussion
Although the effectiveness of hypomethylating agents
in MDS has been reported from several prospective phase
II and III clinical trials in Western countries,9,10,12,13,18-20 a
prospective study has not yet been carried out in Asia.
Published papers have shown possible differences in bio-
logical features of MDS between patients from Western
countries21-23 and those from Asia.24-26 Asian MDS patients
are younger and have a much lower incidence of isolated
5q- syndrome. DIVA (current study) is the first prospective
study to demonstrate the effectiveness of hypomethylat-
ing agents in Asian MDS patients. Our study results are
similar to those of the ADOPT trial, which was a multi-
center, phase II, clinical trial from the United States to
investigate the 5-day outpatient regimen of decitabine in
MDS.13 Table 3 summarizes the eligibility criteria,
Decitabine in Korean patients with MDS
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Table 3. Comparison of DIVA study (current study) with ADOPT trial.13
DIVA study ADOPT trial
N. patients 101 99
Median age, years 65 (23-80) 72 (34-87) 
Eligibility WHO MDS (IPSS ≥ 0.5)  FAB MDS 
+ CMML (IPSS ≥ 0.5)
IPSS category INT-1 52%, Low 1%, INT-1 53%,
INT-2 34%, High 12% INT-2 23%, High 23%
Decitabine regimen 20 mg/m2/d x 5d 20 mg/m2/d x 5d 
every 4 wks every 4 wks 
N. courses, median (range) 5 (1-18) 5 (1-17) 
Treatment response
CR 13% 17%
PR 1% 0%
mCR 23% 15%
HI 19% 18%
ORR (CR/PR/mCR/HI) 55% 51%
SD 11% 24%
Failure 7% 10%
NA 27% 15%
Overall survival
1-year probability 78.6% 66%
Median 17.7 months 19.4 months 
WHO MDS: myelodysplastic syndrome defined by the World Health Organization classi-
fication; IPSS:  International Prognostic Scoring System; CMML: chronic myelomonocytic
leukemia; FAB MDS: MDS defined by French-American-British classification; INT: inter-
mediate; wks: weeks; CR: complete response; PR: partial response; mCR: marrow CR;
ORR: overall response rate; SD: stable disease; NA: not assessable.
Figure 3. Overall survival according to achievement of HI. (A) Total
patients. (B) Higher risk patients (IPSS INT-2/High risk). (C) Lower
risk patients (IPSS INT-1 risk). P value by landmark analysis with the
landmark set at six months from the initial date of decitabine treat-
ment. HI: hematologic improvement; IPSS: International Prognostic
Scoring System; INT: intermediate.
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decitabine regimen, and treatment results of both studies.
Both studies used the same 5-day regimen, which seemed
to result in better response rates and survival than the 3-
day regimen.27
In our study, achievement of HI was important for over-
all survival (Figure 3). This finding suggests that decitabine
treatment might prolong survival in patients achieving HI.
However, our study was not a randomized trial and did
not have a non-treated control group; response to
decitabine could just have been a marker for better risk
disease. The effects of HI on survival were significant in
patients with higher risk disease (IPSS INT-2/High risk),
but not in those with lower risk disease (IPSS INT-1 risk).
Our findings appear to be in line with the results from pre-
vious randomized trials, which have demonstrated signif-
icant prolongation of overall survival or time to
AML/death by hypomethylating agents in higher risk
MDS, but not in lower risk disease.9,18 Therefore, the goal
of hypomethylating therapy in MDS must be tailored to
the disease risk group: survival prolongation in higher risk
MDS and improvement of cytopenia in lower risk MDS. 
Standardized response criteria in MDS was proposed by
the International Working Group (IWG) in 200028 and the
criteria were modified by the same group in 2006.15 The
modified IWG response criteria (IWG 2006) provided a
new definition of mCR which indicated a reduction in
bone marrow myeloblasts to 5% or less and a decrease by
50% or more from pre-treatment levels. However, clinical
significance of mCR has not been well evaluated. In our
study, 23 patients (22.8%) satisfied the response criteria
for mCR: 15 of 23 mCRs were accompanied with HI and
8 were not. Patients with mCR showed inferior survival to
those with CR or PR and similar survival to those with HI
or SD. Survival of patients with mCR differed according to
presence of HI (Figure 2). Thus, mCR itself appeared not
to have as much clinical significance on patients’ out-
comes as HI in non-transplant settings, although mCR
may be of value in allogeneic HCT recipients.13 The issue
of mCR should be examined in future trials. 
Previous study results suggest that treatment duration
may be important in prolonging survival by hypomethy-
lating treatment in MDS. The only randomized clinical
trial to prove the survival benefits provided by a
hypomethylating agent in higher risk MDS was the AZA-
001 trial, in which a median of 9 azacitidine treatment
courses were given.18 In comparison to the AZA-001 trial,
only a median of 4 decitabine treatment courses were
given in the GMDSSG/EORTC 06011 trial, with 40% of
patients receiving 2 courses or less; this meant that the
trial failed to prove survival benefits of a hypomethylating
agent in elderly patients with higher risk MDS.11 In our
study, a median of 5 treatment courses were given and
27% of the patients received one or 2 courses. Among rea-
sons given for discontinuation of decitabine treatment
before the 3rd course, half were due to adverse effects or
personal reasons. Major adverse events were cytopenia
and cytopenia-related infection. Effective measures to pre-
vent complications of infection may lead to prolonging the
duration of decitabine treatment. In a retrospective study
from Korea, antibiotic prophylaxis reduced the incidence
of febrile episodes in patients who received decitabine
treatment for MDS, especially at earlier cycles and in the
presence of severe cytopenia.14 Thus, antibiotic prophylax-
is may be a major supportive measure to avoid the early
discontinuation of decitabine treatment and may thus
help prolong survival. 
In conclusion, decitabine treatment was feasible and
effective in Korean patients with MDS, and OS was signif-
icantly longer in patients showing hematologic improve-
ment.
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